A Study to Investigate the Effect of Impaired Hepatic Function on the Pharmacokinetics of Entrectinib in Volunteers With Different Levels of Hepatic Function

  • Metabolic Disorder
  • Hepatic Insufficiency
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:


This trial runs in
  • Bratislavský kraj
  • Hlavní město Praha
  • Miskolc
Trial Identifier:

NCT04226833 2019-003065-17 GP41174

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This is a non-randomized, open-label, one treatment, four group, parallel group study to investigate the effect of impaired hepatic function on the pharmacokinetics of entrectinib in participants with different levels of hepatic function. Participants with mild, moderate or severe hepatic impairment ('Mild', 'Moderate' and 'Severe' groups), and control participants with normal hepatic function ('Normal' group) will each receive a single 100 mg dose of entrectinib after consumption of a standardized meal.

      Hoffmann-La Roche Sponsor
      Phase 1 Phase
      NCT04226833,GP41174,2019-003065-17 Trial Identifier
      entrectinib Treatments
      Hepatic Insufficiency Condition
      Official Title

      An Open-Label, One Treatment, Four Group, Parallel Group Study to Investigate the Effect of Impaired Hepatic Function on the Pharmacokinetics of Entrectinib in Volunteers With Different Levels of Hepatic Function

      Eligibility Criteria

      All Gender
      ≥18 Years & ≤ 75 Years Age
      Accepts Healthy Volunteers Healthy Volunteers
      Inclusion Criteria

      All participants:

      • A body mass index (BMI) between 18.0 and 38.0 kg/m2, and weighing at least 50 kg
      • Agreement to comply with measures to prevent pregnancy and restrictions on sperm donation.

      Participants with normal hepatic function:

      • Normal hepatic function and no history of clinically significant hepatic dysfunction.
      • Healthy for age-group in the opinion of the Investigator.

      Participants with hepatic impairment:

      • Mild, moderate or severe hepatic dysfunction (i.e. Child-Pugh A, B or C, NCIODWG Mild, Moderate or Severe) arising from cirrhosis of the liver as the result of parenchymal liver disease.
      • Stable hepatic function.
      Exclusion Criteria
      • Transjugular intrahepatic portosystemic shunt or other porta-caval shunt.
      • A history of gastrointestinal hemorrhage due to esophageal varices or peptic ulcers.
      • Recent history or signs of severe hepatic encephalopathy (e.g., a portal systemic encephalopathy score >2).
      • Advanced ascites or ascites which require emptying and albumin supplementation.
      • Hepatocellular carcinoma, acute liver disease or serum ALT or AST not consistent with stable disease.
      • Recipient of a liver transplant.
      • Uncontrolled hypertension.
      • Clinically significant impairment of renal function.
      • A history of gastrointestinal surgery or other gastrointestinal disorder that might affect absorption of medicines from the gastrointestinal tract.
      • Clinically significant change in health status, or any major illness, or clinically significant acute infection or febrile illness.
      • Women who are pregnant or lactating.
      • Presence of any abnormal ECG finding, which is clinically significant.
      • Use of moderate or potent inhibitors or inducers of cytochrome P450 3A4 enzyme.
      • Participation in any other clinical study involving administration of an investigational medicinal product or use of an unapproved device.
      • A positive test result for human immunodeficiency virus (HIV).
      • Known history of clinically significant hypersensitivity, or severe allergic reaction, to entrectinib or related compounds or other excipients in the entrectinib formulation.

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now